This new cancer treatment technology applies ultra-low voltage encoded cellular signals (treatment-codes)
The technology takes advantage of the fact that malignant cancer cells communicate with one-another. This makes it possible for treatment-codes to be transmitted from cancer cell to cancer cell, wrecking and shutting-down its cellular electrical communication process.
C3 is the licensee of the cancer treatment approach covered in four pending patent applications based on the neuro-code signaling technology of inventors Eleanor Schuler, et al. C3 currently has the exclusive rights in the United States and China for this cancer killing technology.
Other pending U.S. patent applications are as follows:
U.S. Patent Application Serial No. 12/334,212 entitled “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.
U.S. Patent Application Serial No. 12/936,778 entitled “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.
U.S. Patent Application Serial No. 12/812,576 entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”
This cancer killing technology has the potential to replace current chemotherapy surgery and radiation approaches and represents the dawn of an entirely new treatment approach using ultra-low voltage encoded signals to destroy cancer directly and quickly. This new and exciting breakthrough is based on the fact that all cells communicate, including cancer cells. This approach will “signal” the cancer cells to kill themselves.
About Cancer-Code Corporation
C3, located in Albuquerque, NM, is focusing on the development and testing of cancer treatment technology that takes advantage of the fact that all cells have an electrical process and adjacent cells communicate with one another. The approach of C3 is geared toward disrupting this cancer cell communication and “wrecking"
Additional information about C3 can be found at:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for products flowing out of C3’s approach, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.
Cancer Code Corporation
117 Bryn Mawr Dr S.E.
Albuquerque, NM 87106
Tel. (505) 314-1300